Literature DB >> 15549297

FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis.

Mariëtte C A van Kouwen1, Jan B M J Jansen, Harry van Goor, Steve de Castro, Wim J G Oyen, Joost P H Drenth.   

Abstract

PURPOSE: 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) is an imaging technique which enables detection of malignancies. FDG-PET has been established as a tool for the diagnosis of pancreatic carcinoma (CA). Early detection is mandatory as cure can only be achieved in non-advanced disease. This is, however, very difficult with conventional radiological techniques. Patients with chronic pancreatitis (CP) are at risk of developing CA. A simple, reliable screening method for malignant degeneration is highly desirable. We set out to investigate whether FDG-PET is able to detect CA in the setting of CP and can fulfil a potential role in the early detection of CA in CP.
METHODS: FDG-PET was performed in 77 CP patients and in six patients with CP complicated by CA (CP + CA). We included 26 CA patients as a positive control. A positive scan was defined as focal FDG accumulation in the pancreas region.
RESULTS: In 67 of the 77 CP (87%) patients, pancreatic FDG accumulation was absent. Six patients had significant accumulation. In CA, 24/26 patients had a positive PET. Five out of the six patients with CP + CA had focal uptake, while minor uptake was seen in one patient. FDG-PET was positive in almost all CA patients and CP + CA patients. FDG-PET was negative in the large majority (87%) of CP patients, which suggests that a positive PET scan in CP patients must lead to efforts to exclude a malignancy.
CONCLUSION: These data suggest that FDG-PET has a potential role as a diagnostic tool for detecting CA in longstanding CP.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15549297     DOI: 10.1007/s00259-004-1689-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  32 in total

Review 1.  Genetics of chronic pancreatitis.

Authors:  Heiko Witt; Michael Becker
Journal:  J Pediatr Gastroenterol Nutr       Date:  2002-02       Impact factor: 2.839

2.  Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer.

Authors:  A Imdahl; E Nitzsche; F Krautmann; S Högerle; S Boos; A Einert; J Sontheimer; E H Farthmann
Journal:  Br J Surg       Date:  1999-02       Impact factor: 6.939

3.  Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis.

Authors:  H Witt; W Luck; H C Hennies; M Classen; A Kage; U Lass; O Landt; M Becker
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

4.  Pancreatic cancer or chronic pancreatitis? An answer from PET/MRI image fusion.

Authors:  Alberto Malesci; Luca Balzarini; Arturo Chiti; Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-10       Impact factor: 9.236

5.  Biliary tract FDG uptake secondary to stent placement.

Authors:  Eugene C Lin; Matthew Studley
Journal:  Clin Nucl Med       Date:  2003-04       Impact factor: 7.794

6.  Mutations in serine protease inhibitor Kazal type 1 are strongly associated with chronic pancreatitis.

Authors:  J P H Drenth; R te Morsche; J B M J Jansen
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

7.  The role of anti-p53-autoantibodies in pancreatic disorders.

Authors:  S Gansauge; F Gansauge; G Negri; P Galle; J Müller; A K Nüssler; B Poch; H G Beger
Journal:  Int J Pancreatol       Date:  1996-06

8.  Detection of liver metastases from pancreatic cancer using FDG PET.

Authors:  A Fröhlich; C G Diederichs; L Staib; J Vogel; H G Beger; S N Reske
Journal:  J Nucl Med       Date:  1999-02       Impact factor: 10.057

9.  Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US.

Authors:  T Inokuma; N Tamaki; T Torizuka; Y Magata; M Fujii; Y Yonekura; T Kajiyama; G Ohshio; M Imamura; J Konishi
Journal:  Radiology       Date:  1995-05       Impact factor: 11.105

10.  Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis.

Authors:  A Malesci; M A Tommasini; C Bonato; P Bocchia; M Bersani; A Zerbi; E Beretta; V Di Carlo
Journal:  Gastroenterology       Date:  1987-01       Impact factor: 22.682

View more
  17 in total

1.  Preoperative 18[F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection.

Authors:  Kojun Okamoto; Isamu Koyama; Mitsuo Miyazawa; Yasuko Toshimitsu; Masayasu Aikawa; Katsuya Okada; Etsuko Imabayashi; Hiroshi Matsuda
Journal:  Int J Clin Oncol       Date:  2010-09-23       Impact factor: 3.402

2.  FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis.

Authors:  Zhen Wang; Jun-Qiang Chen; Jin-Lu Liu; Xin-Gan Qin; Yuan Huang
Journal:  World J Gastroenterol       Date:  2013-08-07       Impact factor: 5.742

3.  PET imaging of inflammation and adenocarcinoma xenografts using vascular adhesion protein 1 targeting peptide 68Ga-DOTAVAP-P1: comparison with 18F-FDG.

Authors:  Anu Autio; Tiina Ujula; Pauliina Luoto; Satu Salomäki; Sirpa Jalkanen; Anne Roivainen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-04       Impact factor: 9.236

4.  The role of 18F-fluorodeoxyglucose positron emission tomography in the management of patients with pancreatic adenocarcinoma.

Authors:  Lujaien A Kadhim; Avani S Dholakia; Joseph M Herman; Richard L Wahl; Muhammad A Chaudhry
Journal:  J Radiat Oncol       Date:  2013-10-30

Review 5.  Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer.

Authors:  Xiao-Yi Wang; Feng Yang; Chen Jin; De-Liang Fu
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

6.  Quantification of tumour (18) F-FDG uptake: Normalise to blood glucose or scale to liver uptake?

Authors:  Georgia Keramida; Sabina Dizdarevic; Janice Bush; A Michael Peters
Journal:  Eur Radiol       Date:  2015-04-22       Impact factor: 5.315

7.  Pancreatic carcinoma coexisting with chronic pancreatitis versus tumor-forming pancreatitis: diagnostic utility of the time-signal intensity curve from dynamic contrast-enhanced MR imaging.

Authors:  Yoshitsugu Tajima; Tamotsu Kuroki; Ryuji Tsutsumi; Ichiro Isomoto; Masataka Uetani; Takashi Kanematsu
Journal:  World J Gastroenterol       Date:  2007-02-14       Impact factor: 5.742

8.  Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer.

Authors:  A Quon; S T Chang; F Chin; A Kamaya; D W Dick; B W Loo; S S Gambhir; A C Koong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-25       Impact factor: 9.236

Review 9.  [PET and PET-CT of malignant tumors of the exocrine pancreas].

Authors:  S N Reske
Journal:  Radiologe       Date:  2009-02       Impact factor: 0.635

10.  Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography.

Authors:  Yayoi Ozaki; Kazuhiro Oguchi; Hideaki Hamano; Norikazu Arakura; Takashi Muraki; Kendo Kiyosawa; Mitsuhiro Momose; Masumi Kadoya; Kazunobu Miyata; Takao Aizawa; Shigeyuki Kawa
Journal:  J Gastroenterol       Date:  2008-02-29       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.